Ref. No.: EIKO/BSE/2023-24/47

Date: 02<sup>nd</sup> January, 2024

To,
Corporate Services Department,
BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: 540204

Dear Sir/ Ma'am,

Sub: Submission of Corrigendum to the Newspaper Advertisement for First and Final Call Notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to captioned subject, this is to inform that a corrigendum to the advertisement in connection with the First and Final Call Notice is published in the following newspapers on  $02^{nd}$  January,2024:

- 1. Business Standard
- 2. Mumbai Lakshadweep

We are submitting herewith copy of e-clippings of the corrigendum published in above mentioned newspaper for your records.

This is for your information and records.

Thanking You,

Yours Faithfully,

For Eiko Lifesciences Limited

JAID ISMAIL Digitally signed by JAID ISMAIL KOJAR
KOJAR

Date: 2024.01.02
14:28:01 +05'30'

Jaid Ismail Kojar Chief Financial Officer

## **EIKO LIFESCIENCES LIMITED**

CIN: L65993MH1977PLC258134;

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar
Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India;
Contact Details: +91 9320171272;

Email-ID: investor.relations@eikolifesciences.com;
Website: www.eikolifesciences.com
CFO: Mr. Jaid Ismail Kojar, PROMOTERS OF OUR COMPANY:
Mr. Laxmikant Ramprasad Kabra and Mr. Bhavesh Dhirajlal Tanna

CORRIGENDUM TO PUBLIC ANNOUNCEMENT DATED

29<sup>TH</sup> DECEMBER, 2023 FOR THE ATTENTION OF THE
REGISTERED MEMBERS OF PARTLY PAID UP SHARES HELD AS
ON CALL RECORD DATE I.E FRIDAY, 22<sup>ND</sup> DECEMBER, 2023

## REVISION IN FIRST AND FINAL CALL PERIOD

	From	То
Call Payment	Wednesday,	Wednesday,
Period	03 <sup>rd</sup> January, 2024	17 <sup>th</sup> January, 2024

\*Except for the above, all the information as mentioned in the advertisement dated 29th December, 2023 remain unchanged.

The Company has intimated the revised schedule to the Stock Exchange on  $01^{\star}$  January, 2024.

For Eiko Lifesciences Limited

Place: Mumbal Jaid Kojar
Date: 02<sup>nd</sup> January, 2024 Chief Financial Officer

माझे (हर) (११०) मासे (११०)

आः न्याः सनश् र्व,

कडे हांदर

)0१ ।धीर ,**क**न स्या

वल का ठकतं च्या दावे संबंध जर आर्थ सूचन

एअ ग अ गमी ज्या विरी गएप DF( DF( **ॲवेन** ।/बां

१९, एपीएमसी मार्केट १, फेझ-२, वाशी (पुर्वीचे तुर्ये), to have been waived and/or abandoned.

## EIKO LIFESCIENCES LIMITED

CIN: L65993MH1977PLC258134; Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India; Contact Details: +91 9320171272;

Email-ID: investor.relations@eikolifesciences.com; Website: www.eikolifesciences.com

CFO: Mr. Jaid Ismail Kojar, PROMOTERS OF OUR COMPANY: Mr. Laxmikant Ramprasad Kabra and Mr. Bhavesh Dhirajlal Tanna CORRIGENDUM TO PUBLIC ANNOUNCEMENT DATED

29<sup>™</sup> DECEMBER, 2023 FOR THE ATTENTION OF THE REGISTERED MEMBERS OF PARTLY PAID UP SHARES HELD AS ON CALL RECORD DATE I.E FRIDAY, 22<sup>ND</sup> DECEMBER, 2023

REVISION IN FIRST AND FINAL CALL FERIOD			
	From	То	
Call Payment	Wednesday,	Wednesday,	
Period	03 <sup>rd</sup> January, 2024	17 <sup>th</sup> January, 2024	

\*Except for the above, all the information as mentioned in the advertisement dated 29th December, 2023 remain unchanged.

The Company has intimated the revised schedule to the Stock Exchange on 01<sup>st</sup> January, 2024.

For Eiko Lifesciences Limited Place: Mumbal Jaid Kojar Date: 02<sup>nd</sup> January, 2024 **Chief Financial Officer**